David Simonnet finally has his first samples of adrenaline.
It took a year for his company, Axyntis, to develop the manufacturing process for this active ingredient, which is found in several drugs used in intensive care and anesthesia.
Products that came close to shortage in hospitals during the first wave of Covid.
Full-scale production is expected to start in the second half.
Ultimately, Axyntis plans to cover more than half of French needs.
To discover
YOUR COMMUNE - The results of the second round of the presidential election in your area
Taxes 2022: all about your tax return
This French ETI (intermediate-sized company) specializing in fine chemicals got to work as soon as it won the government's call for expressions of interest in February 2021. Adrenaline is one of the eight molecules that Axyntis has undertaken to relocate to France.
In total, the company will invest 6 million euros, 60% financed by public funds, on its site in Pithiviers (Loiret).
37 people will be recruited.
The production of these eight molecules…
This article is for subscribers only.
You have 68% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login
